Skinvisible (SKVI) has provided an update.
On May 29, 2024, a press release announced the filing of a Provisional Patent Application for a novel transdermal delivery composition designed to administer obesity drugs using proprietary technology, Invisicare. The development could potentially enhance the delivery of CB-1 receptor antagonists and GLP-1 receptor agonists, marking a significant advancement in obesity treatment options. This information, while not considered filed under the Securities Exchange Act, indicates a forward step for the company in the healthcare market.
For an in-depth examination of SKVI stock, go to TipRanks’ Stock Analysis page.
